{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["SARS-CoV-2", "TCM modernization research", "leupeptin", "main protease", "plants, microbiome, and microbial metabolites ecosystem"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34579576", "DateCompleted": {"Year": "2021", "Month": "11", "Day": "29"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "09", "Day": "28"}], "Language": ["eng"], "ELocationID": ["e02220-21", "10.1128/mBio.02220-21"], "Journal": {"ISSN": "2150-7511", "JournalIssue": {"Volume": "12", "Issue": "5", "PubDate": {"Year": "2021", "Month": "Oct", "Day": "26"}}, "Title": "mBio", "ISOAbbreviation": "mBio"}, "ArticleTitle": "Mechanism of Microbial Metabolite Leupeptin in the Treatment of COVID-19 by Traditional Chinese Medicine Herbs.", "Pagination": {"StartPage": "e0222021", "MedlinePgn": "e0222021"}, "Abstract": {"AbstractText": ["Coronavirus disease 2019 (COVID-19) has caused huge deaths and economic losses worldwide in the current pandemic. The main protease (M<sup>pro</sup>) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is thought to be an ideal drug target for treating COVID-19. Leupeptin, a broad-spectrum covalent inhibitor of serine, cysteine, and threonine proteases, showed inhibitory activity against M<sup>pro</sup>, with a 50% inhibitory concentration (IC<sub>50</sub>) value of 127.2\u2009\u03bcM <i>in vitro</i> in our study here. In addition, leupeptin can also inhibit SARS-CoV-2 in Vero cells, with 50% effective concentration (EC<sub>50</sub>) values of 42.34\u2009\u03bcM. More importantly, various strains of streptomyces that have a broad symbiotic relationship with medicinal plants can produce leupeptin and leupeptin analogs to regulate autogenous proteases. Fingerprinting and structure elucidation using high-performance liquid chromatography (HPLC) and high-resolution mass spectrometry (HRMS), respectively, further proved that the Qing-Fei-Pai-Du (QFPD) decoction, a traditional Chinese medicine (TCM) formula for the effective treatment of COVID-19 during the period of the Wuhan outbreak, contains leupeptin. All these results indicate that leupeptin at least contributes to the antiviral activity of the QFPD decoction against SARS-CoV-2. This also reminds us to pay attention to the microbiomes in TCM herbs as streptomyces in the soil might produce leupeptin that will later infiltrate the medicinal plant. We propose that plants, microbiome, and microbial metabolites form an ecosystem for the effective components of TCM herbs. <b>IMPORTANCE</b> A TCM formula has played an important role in the treatment of COVID-19 in China. However, the mechanism of TCM action is still unclear. In this study, we identified leupeptin, a metabolite produced by plant-symbiotic actinomyces (PSA), which showed antiviral activity in both cell culture and enzyme assays. Moreover, leupeptin found in the QFPD decoction was confirmed by both HPLC fingerprinting and HRMS. These results suggest that leupeptin likely contributes to the antiviral activity of the QFPD decoction against SARS-CoV-2. This result gives us important insight into further studies of the PSA metabolite and medicinal plant ecosystem for future TCM modernization research."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China."}, {"Identifier": [], "Affiliation": "Center for Influenza Research and Early Warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing, China."}], "LastName": "Fu", "ForeName": "Lifeng", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Institute for Radiological Protection, China CDC, Beijing, China."}], "LastName": "Shao", "ForeName": "Shuai", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China."}], "LastName": "Feng", "ForeName": "Yong", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, China."}], "LastName": "Ye", "ForeName": "Fei", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing, China."}, {"Identifier": [], "Affiliation": "Peking University First Hospital, Peking University, Beijing, China."}], "LastName": "Sun", "ForeName": "Xue", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shaanxi Natural Carbohydrate Resource Engineering Research Center, College of Food Science and Technology, Northwest University, Xi'an, China."}], "LastName": "Wang", "ForeName": "Qingling", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China."}], "LastName": "Yu", "ForeName": "Feng", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China."}], "LastName": "Wang", "ForeName": "Qisheng", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, China."}], "LastName": "Huang", "ForeName": "Baoying", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, China."}], "LastName": "Niu", "ForeName": "Peihua", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China."}], "LastName": "Li", "ForeName": "Xuebing", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing, China."}, {"Identifier": [], "Affiliation": "Peking University First Hospital, Peking University, Beijing, China."}, {"Identifier": [], "Affiliation": "Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China."}], "LastName": "Wong", "ForeName": "Catherine C L", "Initials": "CCL"}, {"Identifier": ["0000-0002-9358-4732"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China."}], "LastName": "Qi", "ForeName": "Jianxun", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, China."}], "LastName": "Tan", "ForeName": "Wenjie", "Initials": "W"}, {"Identifier": ["0000-0002-3869-615X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China."}], "LastName": "Gao", "ForeName": "George Fu", "Initials": "GF"}], "GrantList": [{"GrantID": "XDB29010202", "Agency": "CAS | Chinese Academy of Sciences Key Project (CAS Key Project)", "Country": ""}, {"GrantID": "2016YFD0500300", "Agency": "MOST | National Key Research and Development Program of China (973 Program)", "Country": ""}, {"GrantID": "81673358", "Agency": "National Natural Science Foundation of China (NSFC)", "Country": ""}, {"GrantID": "82161148008", "Agency": "National Natural Science Foundation of China (NSFC)", "Country": ""}, {"GrantID": "21807109", "Agency": "National Natural Science Foundation of China (NSFC)", "Country": ""}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "mBio", "NlmUniqueID": "101519231"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Leupeptins"}, {"RegistryNumber": "J97339NR3V", "NameOfSubstance": "leupeptin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Chlorocebus aethiops"}, {"QualifierName": [], "DescriptorName": "Ecosystem"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Leupeptins"}, {"QualifierName": ["methods"], "DescriptorName": "Medicine, Chinese Traditional"}, {"QualifierName": ["drug effects", "pathogenicity"], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "Vero Cells"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H, Zhang Y, Li T, Liu S, Zhang M, Zhao C, Liu H, Nie L, Qin H, Wang M, Lu Q, Li X, Liu J, Liang H, Shi Y, Shen Y, Xie L, Zhang L, Qu X, Xu W, Huang W, Wang Y. 2021. No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants. Cell 184:2362\u20132371.e9. doi:10.1016/j.cell.2021.02.042.", "ArticleIdList": ["10.1016/j.cell.2021.02.042", "PMC7901273", "33735608"]}, {"Citation": "Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O\u2019Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, H\u00fcttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, et al. . 2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459\u2013468. doi:10.1038/s41586-020-2286-9.", "ArticleIdList": ["10.1038/s41586-020-2286-9", "PMC7431030", "32353859"]}, {"Citation": "Chi CW, Liu HZ, Liu CY, Chibber BA, Castellino FJ. 1989. The inhibition of the enzymic activity of blood coagulation and fibrinolytic serine proteases by a new leupeptin-like inhibitor, and its structural analogues, isolated from Streptomyces griseus. J Antibiot (Tokyo) 42:1506\u20131512. doi:10.7164/antibiotics.42.1506.", "ArticleIdList": ["10.7164/antibiotics.42.1506", "2509406"]}, {"Citation": "Kim IS, Lee KJ. 1995. Kinetic study on the production and degradation of leupeptin in Streptomyces exfoliatus SMF13. J Biotechnol 42:35\u201344. doi:10.1016/0168-1656(95)00061-T.", "ArticleIdList": ["10.1016/0168-1656(95)00061-T", "7662340"]}, {"Citation": "Umezawa H, Okami Y, Hotta K. 1978. Transfer of the leupeptin-producing ability of the strain, Streptomyces roseus MA839-A1, by conjugation. J Antibiot (Tokyo) 31:99\u2013102. doi:10.7164/antibiotics.31.99.", "ArticleIdList": ["10.7164/antibiotics.31.99", "627528"]}, {"Citation": "Aoyagi T, Takeuchi T, Matsuzaki A, Kawamura K, Kondo S, Hamada M, Maeda K, Umezawa H. 1969. Leupeptins, new protease inhibitors from Actinomycetes. J Antibiot (Tokyo) 22:283\u2013286. doi:10.7164/antibiotics.22.283.", "ArticleIdList": ["10.7164/antibiotics.22.283", "5810993"]}, {"Citation": "Schr\u00f6der E, Phillips C, Garman E, Harlos K, Crawford C. 1993. X-ray crystallographic structure of a papain-leupeptin complex. FEBS Lett 315:38\u201342. doi:10.1016/0014-5793(93)81128-m.", "ArticleIdList": ["10.1016/0014-5793(93)81128-m", "8416808"]}, {"Citation": "Aoyagi T, Miyata S, Nanbo M, Kojima F, Matsuzaki M. 1969. Biological activities of leupeptins. J Antibiot (Tokyo) 22:558\u2013568. doi:10.7164/antibiotics.22.558.", "ArticleIdList": ["10.7164/antibiotics.22.558", "4243683"]}, {"Citation": "Kerr ID, Lee JH, Pandey KC, Harrison A, Sajid M, Rosenthal PJ, Brinen LS. 2009. Structures of falcipain-2 and falcipain-3 bound to small molecule inhibitors: implications for substrate specificity. J Med Chem 52:852\u2013857. doi:10.1021/jm8013663.", "ArticleIdList": ["10.1021/jm8013663", "PMC2651692", "19128015"]}, {"Citation": "Moldoveanu T, Campbell RL, Cuerrier D, Davies PL. 2004. Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. J Mol Biol 343:1313\u20131326. doi:10.1016/j.jmb.2004.09.016.", "ArticleIdList": ["10.1016/j.jmb.2004.09.016", "15491615"]}, {"Citation": "Kurinov IV, Harrison RW. 1996. Two crystal structures of the leupeptin-trypsin complex. Protein Sci 5:752\u2013758. doi:10.1002/pro.5560050420.", "ArticleIdList": ["10.1002/pro.5560050420", "PMC2143399", "8845765"]}, {"Citation": "Sher JH, Stracher A, Shafiq SA, Hardy-Stashin J. 1981. Successful treatment of murine muscular dystrophy with the proteinase inhibitor leupeptin. Proc Natl Acad Sci USA 78:7742\u20137744. doi:10.1073/pnas.78.12.7742.", "ArticleIdList": ["10.1073/pnas.78.12.7742", "PMC349346", "6950412"]}, {"Citation": "Valderrama R, Chang VK, Stracher A, Maccabee PJ, Kaldany R-RJ. 1987. Treatment of experimental autoimmune myasthenia gravis in rabbits with leupeptin, a protease inhibitor. J Neurol Sci 82:133\u2013143. doi:10.1016/0022-510X(87)90013-X.", "ArticleIdList": ["10.1016/0022-510X(87)90013-X", "3440864"]}, {"Citation": "Appleyard G, Tisdale M. 1985. Inhibition of the growth of human coronavirus 229E by leupeptin. J Gen Virol 66(Part 2):363\u2013366. doi:10.1099/0022-1317-66-2-363.", "ArticleIdList": ["10.1099/0022-1317-66-2-363", "3968542"]}, {"Citation": "Bai Y, Ye F, Feng Y, Liao H, Song H, Qi J, Gao GF, Tan W, Fu L, Shi Y. 2021. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Signal Transduct Target Ther 6:51. doi:10.1038/s41392-021-00468-9.", "ArticleIdList": ["10.1038/s41392-021-00468-9", "PMC7860160", "33542181"]}, {"Citation": "Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, Zhao C, Sun H, Huang B, Niu P, Song H, Shi Y, Li X, Tan W, Qi J, Gao GF. 2020. Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun 11:4417. doi:10.1038/s41467-020-18233-x.", "ArticleIdList": ["10.1038/s41467-020-18233-x", "PMC7474075", "32887884"]}, {"Citation": "Kneller DW, Galanie S, Phillips G, O\u2019Neill HM, Coates L, Kovalevsky A. 2020. Malleability of the SARS-CoV-2 3CL Mpro active-site cavity facilitates binding of clinical antivirals. Structure 28:1313\u20131320.e3. doi:10.1016/j.str.2020.10.007.", "ArticleIdList": ["10.1016/j.str.2020.10.007", "PMC7584437", "33152262"]}, {"Citation": "G\u00fcnther S, Reinke PYA, Fern\u00e1ndez-Garc\u00eda Y, Lieske J, Lane TJ, Ginn HM, Koua FHM, Ehrt C, Ewert W, Oberthuer D, Yefanov O, Meier S, Lorenzen K, Krichel B, Kopicki J-D, Gelisio L, Brehm W, Dunkel I, Seychell B, Gieseler H, Norton-Baker B, Escudero-P\u00e9rez B, Domaracky M, Saouane S, Tolstikova A, White TA, H\u00e4nle A, Groessler M, Fleckenstein H, Trost F, Galchenkova M, Gevorkov Y, Li C, Awel S, Peck A, Barthelmess M, Schl\u00fcnzen F, Lourdu Xavier P, Werner N, Andaleeb H, Ullah N, Falke S, Srinivasan V, Fran\u00e7a BA, Schwinzer M, Brognaro H, Rogers C, Melo D, Zaitseva-Doyle JJ, Knoska J, et al. . 2021. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science 372:642\u2013646. doi:10.1126/science.abf7945.", "ArticleIdList": ["10.1126/science.abf7945", "PMC8224385", "33811162"]}, {"Citation": "Shirato K, Kawase M, Matsuyama S. 2018. Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology 517:9\u201315. doi:10.1016/j.virol.2017.11.012.", "ArticleIdList": ["10.1016/j.virol.2017.11.012", "PMC7112029", "29217279"]}, {"Citation": "Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, M\u00fcller MA, Drosten C, P\u00f6hlmann S. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271\u2013280.e8. doi:10.1016/j.cell.2020.02.052.", "ArticleIdList": ["10.1016/j.cell.2020.02.052", "PMC7102627", "32142651"]}, {"Citation": "Ning MC, Beynon RJ. 1986. Preparation and purification of the proteinase inhibitor, leupeptin, from culture filtrates of Streptomyces lavendulae. Int J Biochem 18:813\u2013820. doi:10.1016/0020-711x(86)90058-3.", "ArticleIdList": ["10.1016/0020-711x(86)90058-3", "3758463"]}, {"Citation": "Kim IS, Lee KJ. 1995. Physiological roles of leupeptin and extracellular proteases in mycelium development of Streptomyces exfoliatus SMF13. Microbiology (Reading) 141(Part 4):1017\u20131025. doi:10.1099/13500872-141-4-1017.", "ArticleIdList": ["10.1099/13500872-141-4-1017", "7773379"]}, {"Citation": "Nakaew N, Lumyong S, Sloan WT, Sungthong R. 2019. Bioactivities and genome insights of a thermotolerant antibiotics-producing Streptomyces sp. TM32 reveal its potentials for novel drug discovery. Microbiologyopen 8:e842. doi:10.1002/mbo3.842.", "ArticleIdList": ["10.1002/mbo3.842", "PMC6854843", "30941917"]}, {"Citation": "Qin S, Xing K, Jiang J-H, Xu L-H, Li W-J. 2011. Biodiversity, bioactive natural products and biotechnological potential of plant-associated endophytic actinobacteria. Appl Microbiol Biotechnol 89:457\u2013473. doi:10.1007/s00253-010-2923-6.", "ArticleIdList": ["10.1007/s00253-010-2923-6", "20941490"]}, {"Citation": "L\u00fc W, Liu C, Huang L, Yan X. 2017. Genome-wide prediction and analysis of the secretory proteins and ORFs signal peptide of ginkgo endophyte KM-1-2. Wei Sheng Wu Xue Bao 57:411\u2013421.", "ArticleIdList": ["29756439"]}, {"Citation": "Liao P, Zhao C, Zhang HN, Liu MK, Penttinen P, Zhang XP, Zhao K. 2016. Diversity and antimicrobial activity of endophytic actinobacteria isolated from Melia toosendan Sieb. et Zucc. Microbiology China 43:2374\u20132385."}, {"Citation": "Ni L, Zhou L, Zhou M, Zhao J, Wang DW. 2020. Combination of Western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front Med 14:210\u2013214. doi:10.1007/s11684-020-0757-x.", "ArticleIdList": ["10.1007/s11684-020-0757-x", "PMC7088740", "32170559"]}, {"Citation": "Du HZ, Hou XY, Miao YH, Huang BS, Liu DH. 2020. Traditional Chinese medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP). Chin J Nat Med 18:206\u2013210. doi:10.1016/S1875-5364(20)30022-4.", "ArticleIdList": ["10.1016/S1875-5364(20)30022-4", "PMC7270732", "32245590"]}, {"Citation": "National Health Commission of the People\u2019s Republic of China. 2020. Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment, 7th ed. National Health Commission of the People\u2019s Republic of China, Beijing, China. http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml."}, {"Citation": "Shi N, Liu B, Liang N, Ma Y, Ge Y, Yi H, Wo H, Gu H, Kuang Y, Tang S, Zhao Y, Tong L, Liu S, Zhao C, Chen R, Bai W, Fan Y, Shi Z, Li L, Liu J, Gu H, Zhi Y, Wang Z, Li Y, Li H, Wang J, Jiao L, Tian Y, Xiong Y, Huo R, Zhang X, Bai J, Chen H, Chen L, Feng Q, Guo T, Hou Y, Hu G, Hu X, Hu Y, Huang J, Huang Q, Huang S, Ji L, Jin H, Lei X, Li C, Wu G, Li J, Li M, et al. . 2020. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study. Pharmacol Res 161:105290. doi:10.1016/j.phrs.2020.105290.", "ArticleIdList": ["10.1016/j.phrs.2020.105290", "PMC7833425", "33181320"]}, {"Citation": "Zhang K. 2020. Is traditional Chinese medicine useful in the treatment of COVID-19? Am J Emerg Med 38:2238. doi:10.1016/j.ajem.2020.03.046.", "ArticleIdList": ["10.1016/j.ajem.2020.03.046", "PMC7138187", "32245701"]}, {"Citation": "National Administration of Traditional Chinese Medicine. 2020. Progress has been made in the screening of effective prescriptions for traditional Chinese medicine. National Administration of Traditional Chinese Medicine, Beijing, China."}, {"Citation": "Schultz RM, Varma-Nelson P, Ortiz R, Kozlowski KA, Orawski AT, Pagast P, Frankfater A. 1989. Active and inactive forms of the transition-state analog protease inhibitor leupeptin: explanation of the observed slow binding of leupeptin to cathepsin B and papain. J Biol Chem 264:1497\u20131507. doi:10.1016/S0021-9258(18)94215-8.", "ArticleIdList": ["10.1016/S0021-9258(18)94215-8", "2912969"]}, {"Citation": "Tan W, Zhao X, Ma X, Wang W, Niu P, Xu W, Gao GF, Wu G. 2020. A novel coronavirus genome identified in a cluster of pneumonia cases\u2014Wuhan, China 2019\u20132020. China CDC Wkly 2:61\u201362. doi:10.46234/ccdcw2020.017.", "ArticleIdList": ["10.46234/ccdcw2020.017", "PMC8393069", "34594763"]}, {"Citation": "Wang C, Horby PW, Hayden FG, Gao GF. 2020. A novel coronavirus outbreak of global health concern. Lancet 395:470\u2013473. doi:10.1016/S0140-6736(20)30185-9.", "ArticleIdList": ["10.1016/S0140-6736(20)30185-9", "PMC7135038", "31986257"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "9", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "11", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "9", "Day": "28", "Hour": "5", "Minute": "29"}, {"Year": "2021", "Month": "9", "Day": "28"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34579576", "PMC8546846", "10.1128/mBio.02220-21"]}}], "PubmedBookArticle": []}